Necessity of epicardial ablation for ventricular tachycardia after sequential endocardial approach
Arian Sultan1, Jakob Lüker1, Boris Hoffmann2
1University of Cologne, Heart Center, Department of Electrophysiology, Germany.
Insights
Epicardial catheter ablation (CA) for ventricular tachycardia (VT) is effective in a small subset of patients after endocardial CA fails. This approach achieved success in 9 of 15 VT cases, highlighting its role when the primary endocardial treatment is insufficient.
Area of Science:
- Electrophysiology
- Cardiology
- Cardiac Ablation
Background:
- Catheter ablation (CA) is a key treatment for ventricular tachycardia (VT) in patients with structural heart disease (SHD) and implantable cardioverter defibrillators (ICDs).
- A subset of patients with VT requires epicardial CA, necessitating evaluation after endocardial approaches.
Purpose of the Study:
- To evaluate the significance and success rate of epicardial CA for VT.
- To assess its utility following a systematic sequential endocardial ablation strategy.
Main Methods:
- Analysis of 160 VT ablation procedures in 126 patients (2009-2012).
- Sequential endocardial CA guided by earliest ventricular activation, pacemap, entrainment, and stimulus-to-QRS interval.
- Acute success assessed by programmed ventricular stimulation; long-term success by ICD interrogation and 24h-Holter ECG.
Main Results:
- Endocardial CA succeeded in 94% of treated VT.
- Epicardial CA was additionally performed in 6% of VT cases, succeeding in 9 out of 15.
- Long-term follow-up (25 months) showed 82% freedom from VT, with 9% experiencing recurrent ICD shocks and 9% mortality.
Conclusions:
- Endocardial CA alone achieves high acute success rates for VT in SHD.
- Additional epicardial CA is required in a small percentage (6%) of VT cases after endocardial failure.
- Epicardial CA should be reserved for cases where endocardial ablation is unsuccessful due to potential complications.
Background:
Catheter ablation (CA) of ventricular tachycardia (VT) is an important treatment option in patients with structural heart disease (SHD) and implantable cardioverter defibrillator (ICD). A subset of patients requires epicardial CA for VT.
Objective:
The purpose of the study was to assess the significance of epicardial CA in these patients after a systematic sequential endocardial approach.
Methods:
Between January 2009 and October 2012 CA for VT was analyzed. A sequential CA approach guided by earliest ventricular activation, pacemap, entrainment and stimulus to QRS-interval analysis was used. Acute CA success was assessed by programmed ventricular stimulation. ICD interrogation and 24h-Holter ECG were used to evaluate long-term success.
Results:
One hundred sixty VT ablation procedures in 126 consecutive patients (114 men; age 65±12years) were performed. Endocardial CA succeeded in 250 (94%) out of 265 treated VT. For 15 (6%) VT an additional epicardial CA was performed and succeeded in 9 of these 15 VT. Long-term FU (25±18.2month) showed freedom of VT in 104 pts (82%) after 1.2±0.5 procedures, 11 (9%) suffered from repeated ICD shocks and 11 (9%) died due to worsening of heart failure.
Conclusions:
Despite a heterogenic substrate for VT in SHD, endocardial CA alone results in high acute success rates. In this study additional epicardial CA following a sequential endocardial mapping and CA approach was performed in 6% of VT. Thus, due to possible complications epicardial CA should only be considered if endocardial CA fails.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy V: Interprofessional Care
Dysrhythmias VI: Management of Dysrhythmias
Cardiopulmonary Resuscitation IV: Pharmacological Management
